Nanjing Epkin Biotechnology

Nanjing Epkin Biotechnology is a clinical-stage biopharmaceutical company based in China, specializing in the development of innovative antibody-based therapies for cancer. The company leverages its proprietary Epkin-Body platform to design bispecific antibodies and recombinant proteins that modulate the immune system, particularly focusing on the CD47-SIRPα axis and T-cell costimulation. Its lead program, EP0031, is a differentiated SIRPα-Fc fusion protein currently undergoing clinical evaluation for solid tumors and lymphomas in both China and the United States. Epkin's pipeline also includes several bispecific antibodies targeting PD-L1 in combination with other immune checkpoints or tumor antigens to overcome the limitations of current immunotherapies. The company is committed to advancing its pipeline through internal R&D and strategic collaborations to provide effective treatments for patients worldwide.